Resources

Facility dedicated to cryopreservation of leukapheresis starting materials to support clinical and commercial cell-based therapy programs

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL

New data shows investing in life sciences produces great returns, London Life Sciences Week and #bioProcessUK are nearly here.

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

UK General Election and what it might mean for the industry, including Labour's pledges on Brexit and business taxes. Upcoming events including the Cambridge Wide Open Day and the Life Science Leadership Summit. UK tech companies pitching at the London Stock Exchange and Amber Therapeutics securing $100 million in funding.

MSD Merck acquire UK biotech EyeBio for $1.3 billion upfront, ASCO and BIO conference week and the UK General election campaign produces little news for the life science sector.

The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

I return from holiday to the news that Abcam, a key British life science company founded in 1998, is to be acquired by Danaher, bringing to a conclusion a headline-grabbing intervention this year by founder Jonathan Milner. Once again, this shows the global attractiveness of a global life science company built in the UK. Continue reading...

I’m in Boston with over 200 UK companies at the annual BIO International Convention this week. It is great to see such a vibrant and positive UK presence and I’m looking forward to promoting the excellence of our ecosystem on this global stage. Read on about the core UK message at BIO this week, and details on the launch of our VPAS report.

The annual BIO International Convention is just 3 weeks away and being back in Boston, there is more than ever going on. The conference runs from Monday 5 June to Thursday 8 June taking place at the Boston Convention Center and there will be a significant UK presence at this global event.

The long-awaited and much-leaked European Commission's pharmaceutical legislation was finally published last week. Most of the new proposals have received a hearty thumbs down from the industry due to concerns that the proposals will limit intellectual property. The EU may be one regulated market but it remains a complex patchwork of national healthcare systems, clinical communities and currencies which do not lend themselves, nor seek to be a homogeneous whole. From a UK perspective, the UK has increased its attractiveness as a market simply by standing still, and I have to admit I didn’t think that it would be direct moves by the EU that would make the case for Brexit. Read more on LIFTS, VPAS and HSBC SVB UK...

President Biden issued an executive order in September which aims to catalyse the growth of the US bioeconomy. Herbie Lambden, Policy and Public Affairs Executive at BIA, investigates the policies and what they could mean for UK companies.